Celldex Therapeutics (CLDX) Cash from Investing Activities (2010 - 2026)

Celldex Therapeutics' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $72.1 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 67.91% year-over-year to $72.1 million; the TTM figure through Mar 2026 stood at $238.2 million (up 250.19% YoY), while the FY2025 annual figure was $209.1 million, up 172.06% from the prior year.
• Cash from Investing Activities was $72.1 million for Q1 2026 at Celldex Therapeutics, up from $55.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $72.1 million in Q1 2026 to a low of -$315.2 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$1.5 million across 5 years, with a median of $25.3 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities surged 406.45% in 2023, then tumbled 4114.0% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at $31.2 million in 2022, then sank by 648.36% to -$171.2 million in 2023, then jumped by 114.05% to $24.0 million in 2024, then jumped by 130.49% to $55.4 million in 2025, then soared by 30.12% to $72.1 million in 2026.
• The last three Cash from Investing Activities figures came in at $72.1 million (Q1 2026), $55.4 million (Q4 2025), and $60.8 million (Q3 2025), per Business Quant data.